Verition Fund Management’s Maravai LifeSciences MRVI Stock Holding History

Verition Fund Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.85M	Buy	+777,738	New	+$3.36M	0.02%	676
2024 Q3	–	Sell	-60,037	Closed	-$430K	–	3408
2024 Q2	$430K	Buy	+60,037	New	+$518K	﹤0.01%	2138
2023 Q3	–	Sell	-153,946	Closed	-$1.91M	–	2554
2023 Q2	$1.91M	Buy	153,946 +139,955	+1,000%	+$1.89M	0.03%	689
2023 Q1	$196K	Sell	13,991 -8,892	-39%	-$128K	﹤0.01%	1776
2022 Q4	$327K	Buy	+22,883	New	+$360K	0.01%	1452
2022 Q3	–	Sell	-32,244	Closed	-$916K	–	3164
2022 Q2	$916K	Buy	32,244 +6,020	+23%	+$191K	0.02%	1078
2022 Q1	$925K	Buy	+26,224	New	+$879K	0.01%	1522
2021 Q3	–	Sell	-5,850	Closed	-$244K	–	2173
2021 Q2	$244K	Buy	+5,850	New	+$227K	﹤0.01%	1459

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Verition Fund Management's MRVI Position: Q2 2026 in Review

Verition Fund Management opened a new position in Maravai LifeSciences (MRVI) in Q2 2026: 777,738 shares worth $4.85M. The stake represents 0.02% of the portfolio and ranks #676 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in MRVI as recently as Q2 2024.

Verition Fund Management first reported a position in MRVI in Q2 2021 and has held it in 8 quarters since. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Verition Fund Management held 777,738 shares of Maravai LifeSciences worth $4.85M as of Q2 2026.
Maravai LifeSciences was a new Verition Fund Management position in Q2 2026.
Maravai LifeSciences made up 0.02% of Verition Fund Management's portfolio in Q2 2026, its #676 holding.
Verition Fund Management first reported a position in Maravai LifeSciences in Q2 2021 and has held it in 8 quarters since.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.